MAX Chat
Akums Drugs and Pharmaceutical
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 51.27 | -100% | 0 | 0% |
| P/S |
|
0 | 5.26 | -100% |
|
|
| P/BV |
|
0 | 6.6 | -100% |
|
|
| P/FCF |
|
0 | 165.35 | -100% |
|
|
| Ev/Ebitda |
|
0 | 13.05 | -100% |
|
|
| Ev/S |
|
0 | 4.72 | -100% |
|
|
| Ev/FCF |
|
0 | 162.44 | -100% |
|
|
| E/P |
|
0 | 0.0469 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 20.26 | -100% | 0 | 0% |
| ROE |
|
0 | 21.44 | -100% |
|
|
| ROA |
|
0 | 12.52 | -100% |
|
|
| ROIC |
|
0 | 16.48 | -100% |
|
|
| ROS |
|
0 | 16.94 | -100% |
|
|
| ROCE |
|
0 | 3.91 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | 1.07 | -100% | 0 | 0% |
| Nеt Debt/Ebitda |
|
0 | 0.9268 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.1422 | -100% |
|
|
| Debt/Equity |
|
0 | 0.8709 | -100% |
|
|
| Debt/Net Income |
|
0 | 7.2 | -100% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.15 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.9692 | -100% | ||
| DSI |
|
0 | 0.8388 | -100% |
|
|
| Average dividend growth |
|
0 | -99.59 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.42 | -100% |
|
|
| Average percentage for payments |
|
0 | 30.31 | -100% |
|
|
| Difference from average difference in sector |
|
-1.15 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 75.93 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
0 | 43.18 | -100% | ||
| Growth impulse Net Income in 5 years |
|
0 | 147.83 | -100% | ||
| Growth impulse FCF in 5 years |
|
0 | 94.68 | -100% | ||
| Growth impulse EPS in 5 years |
|
0 | 113.18 | -100% |
IP Score
2.5/10
